Anzeige
Mehr »
Login
Donnerstag, 24.04.2025 Börsentäglich über 12.000 News von 692 internationalen Medien
Jetzt knallt's an der Börse! Diese Aktie hat das Zeug zum Überflieger!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DXS6 | ISIN: US1711261057 | Ticker-Symbol:
NASDAQ
23.04.25
18:23 Uhr
1,450 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
CHANNEL THERAPEUTICS CORPORATION Chart 1 Jahr
5-Tage-Chart
CHANNEL THERAPEUTICS CORPORATION 5-Tage-Chart

Aktuelle News zur CHANNEL THERAPEUTICS CORPORATION Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.04.Ligand's Pelthos unit joins forces with Channel Therapeutics in merger centered on launch of molluscum gel Zelsuvmi1
17.04.Ligand unit Pelthos to merge with Channel Therapeutics1
17.04.Ligand, Channel Therapeutics Agree To Combine Pelthos, LNHC With CHRO Merger Sub 284WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) Thursday announced a definitive merger agreement with Channel Therapeutics Corp. (CHRO) to combine Ligand's wholly owned subsidiaries...
► Artikel lesen
17.04.Channel Therapeutics Corp - 8-K, Current Report1
17.04.Ligand Pharmaceuticals: Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics125Proposed transaction will raise $50 million in equity capital and enhance a publicly traded biopharmaceutical company focused on launching Pelthos' ZELSUVMI ZELSUVMI is an FDA-designated novel drug...
► Artikel lesen
27.03.Channel Therapeutics Corp - 10-K, Annual Report2
CHANNEL THERAPEUTICS CORPORATION Aktie jetzt für 0€ handeln
03.03.Channel Therapeutics Corp - 8-K, Current Report-
20.12.24Channel Therapeutics advances non-opioid pain treatment1
20.12.24Channel Therapeutics erzielt Fortschritte bei nicht-opioidhaltiger Schmerztherapie6
20.12.24Channel Therapeutics Corporation: Channel Therapeutics Highlights Differences Between NaV1.7 and NaV1.8 in Light of Recent Clinical Data on Suzetrigine157FREEHOLD, N.J., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics...
► Artikel lesen
18.12.24Channel Therapeutics Corporation: Channel Therapeutics Announces Positive Efficacy Data For a Depot Formulation of a NaV1.7 Inhibitor in a Preclinical In Vivo Nerve Block Model159FREEHOLD, N.J., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Channel Therapeutics Corporation, ("Channel" or the "Company"), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics...
► Artikel lesen
21.11.24Chromocell Therapeutics Announces Name Change to Channel Therapeutics Corporation and Provides Therapeutic Program Updates189"Channel Therapeutics" reflects the Company's focus on developing therapeutics to treat pain utilizing sodium channel blockade and modulationNew name is in advance of multiple near-term data readouts...
► Artikel lesen
19.11.24Channel Therapeutics finalizes corporate restructuring-
18.11.24Channel Therapeutics Corp - 8-K, Current Report-
13.11.24Chromocell Therapeutics Corp - 10-Q, Quarterly Report-
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1